Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PROTAC-PDAC

Financiado

Targeted Protein Degradation as a New Experimental and Therapeutic Approach for...

Targeted Protein Degradation as a New Experimental and Therapeutic Approach for Pancreatic Ductal Adenocarcinoma Pancreatic ductal adenocarcinoma (PDAC) is a life-threatening disease with few treatment options. Recently, the chemical space for targeted therapeutics was significantly increased by the development of compounds that induce prote... ver más

30/11/2028

CAU

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

CHRISTIANALBRECHTSUNIVERSITAET ZU KIEL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-12

ERC-2022-COG: ERC CONSOLIDATOR GRANTS Scope:Objectives

I+D

Cerrada hace 2 años

0% 100% 100%

2 Participantes

CAU

2.00M€ | Lider

UNI WUERZBURG

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2020-120110RA-I00 DEGRADACION Y LOCALIZACION DIRIGIDA DE PROTEINAS: NUEVAS SOL... 190K€ Cerrado

FJC2020-043715-I Targeted protein degradation: exploring new therapeutic para... Cerrado

PCI2021-122068-2B DRUGGING THE UNDRUGGABLE WITH PROTACS: TARGETING CYCLIN E 161K€ Cerrado

RTI2018-093539-B-I00 PROTACS, TUMOR-TARGETED INHIBITORS AND PROBES FOR CANCER DET... 85K€ Cerrado

SAF2014-53799-C2-1-R LA DEGRADACION DE PROTEINAS MEDIADA POR UBIQUITINACION EN EL... 133K€ Cerrado

SAF2013-48657-R MODULACION DE LA PROGRESION TUMORAL POR ENZIMAS PI3K: APROXI... 484K€ Cerrado

Duración del proyecto: 67 meses Fecha Inicio: 2023-04-12
Fecha Fin: 2028-11-30

Líder del proyecto

CHRISTIANALBRECHTSUNIVERSITAET ZU KIEL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Pancreatic ductal adenocarcinoma (PDAC) is a life-threatening disease with few treatment options. Recently, the chemical space for targeted therapeutics was significantly increased by the development of compounds that induce protein degradation (PROTACs), but so far, they are unavailable for PDAC. The main motivation of PROTAC-PDAC is to develop novel targeted therapies for PDAC. The project is based on our accomplishments in three crucial areas. First, my group identified – as target candidates – a series of transcription factors that are absolutely required for PDAC growth in vivo. Second, we developed dozens of potent, specific PROTACs, thereby gaining deep insight into the underlying design principles and synthesis procedures. Third, we established genetic models in mice for simulating PROTAC function and discovering ideal target–E3 ligase pairs. In PROTAC-PDAC, we will develop compounds that degrade key oncogenic transcription factors and inhibit pancreatic tumor growth with minimal toxicity in healthy tissues. We will start by implementing the Auxin degron system in a murine PDAC model, to induce degradation of the target candidates and select four priority targets with the highest therapeutic index (Aim I). Then, we will assess their oncogenic functions by analyzing molecular, cellular and organismic consequences of acute depletion in mice (Aim II). In parallel, we will develop pharmaceutical PROTACs to induce target degradation and analyze their efficacy in PDAC models (Aim III). Finally, with the aim of developing less toxic PDAC therapy, we will identify pancreatic E3 ligases for the design of the first tissue-specific PROTACs that induce target degradation primarily in pancreatic tumor cells (Aim IV). While the main goal of PROTAC-PDAC is to develop new PROTAC-based therapeutic strategies, we will also establish groundbreaking methods and models leading to fundamental discoveries in PDAC biology.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores